Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Business Update

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update


Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.

Second quarter 2022 Corporate and Operational Highlights:

Corporate Restructuring

Business Development Strategy

Second Quarter MultiStem Clinical Trial Updates

MASTERS-2 (Phase 3 global study in ischemic stroke)

TREASURE (Phase 2/3 Japan study in ischemic stroke)

MATRICS-1 (Phase 2 study in trauma)

MACOVIA (Phase 2/3 study in acute respiratory distress syndrome)

Management Commentary

"My first six months at Athersys have certainly been both challenging and productive," stated Dan Camardo, Chief Executive Officer of Athersys. "While the topline data from the TREASURE study evaluating MultiStem for the treatment of ischemic stroke conducted by our partner Healios in Japan did not reach statistical significance for its primary Endpoint of Excellent Outcome at 90-days, there were important and encouraging takeaways from this trial. We are particularly pleased that the study demonstrated improvement in other pre-specified measures of functional outcomes over time, supporting the long-term impact of MultiStem in ischemic stroke patients. The TREASURE trial results were positively endorsed by stroke key opinion leaders offering further encouragement as we proceed with our own MASTERS-2 study." Camardo continued, "We also implemented a restructuring of our organization with the intention of significantly reducing expenses, conserving cash, improving focus of the Company's activities and creating a positive impact on enrollment progress in our MASTERS-2 study. We are confident that the actions taken over the last two months will better position Athersys in bringing MultiStem to market and becoming a global leader in regenerative medicine."

Second Quarter Results

Revenues increased to $2.3 million for the three months ended June 30, 2022 compared to no revenues for the three months ended June 30, 2021. Our collaboration revenues currently fluctuate from period to period based on the delivery of services under our arrangement with Healios.

Research and development expenses increased to $20.8 million for the three months ended June 30, 2022 from $17.7 million for the comparable period in 2021. The $3.1 million increase is associated with an impairment charge of $4.9 million related to assets that are no longer necessary to support future research and development and restructuring costs of $1.5 million. These increases were partially offset by decreases in clinical trial and manufacturing costs of $2.0 million, internal research supplies of $0.7 million, consulting fees of $0.4 million and decreases in other research development costs of $0.2 million. Our clinical development, clinical manufacturing and manufacturing process development expenses vary over time based on the timing and stage of clinical trials underway, manufacturing campaigns for clinical trials and manufacturing process development projects. These variations in activity level may also impact our accounts payable, accrued expenses, prepaid expenses and deposits balances from period to period. Other than external expenses for our clinical and preclinical programs, we generally do not track our research expenses by project; rather, we track such expenses by the type of cost incurred. We expect our research and development expenses to decrease in connection with our restructuring plan.

General and administrative expenses were $5.2 million for the three months ended June 30, 2022, which was higher than the $4.2 million for the comparable period in 2021. The increase is primarily related to restructuring costs of $1.2 million. We expect our general and administrative expenses to decrease in connection with our restructuring plan.

Net loss for the second quarter of 2022 was $23.6 million compared to a net loss of $22.6 million in the second quarter of 2021. The difference primarily results from the above variances.

During the six months ended months ended June 30, 2022, net cash used in operating activities was $36.6 million compared to $37.2 million in the six months ended months June 30, 2021. At June 30, 2022, we had $13.4 million in cash and cash equivalents, compared to $37.4 million at December 31, 2021.

Conference Call

Athersys will host a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Stockholders are encouraged to listen using this Webcast link. To participate via phone if you intend to ask a question, please pre-register for the conference call using this Call registration link. Registered stockholders will receive the toll-free number, a direct entry passcode and a registrant ID.

A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended. Stockholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 p.m. Eastern time on August 18, 2022, by dialing (888) 330-2506 or (240) 789-2712 and entering the conference code 70781.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has two ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "suggest," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations.

In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risk that we will be unable to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern and our ability to successfully resolve the payment issues with our primary contract manufacturer and gain access to our clinical product. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our collaborators' ability and willingness to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the possibility of unfavorable results from ongoing and additional clinical trials involving MultiStem; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in an early stage clinical trial may not be predictive of results in later stage or large scale clinical trials; our ability to regain compliance with the requirement to maintain a minimum closing bid price of $1.00 per share as set forth in Nasdaq Listing Rule 5550(a)(2); the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of ARDS induced by COVID-19 and other pathogens, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the availability of product sufficient to meet our clinical needs and potential commercial demand following any approval; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors that could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; the success of our efforts to enter into new strategic partnerships and advance our programs; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 under Item 1A, "Risk Factors" and our other filings with the SEC. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

(Tables Follow)

Athersys, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

 

 

 

June 30,
2022

 

December 31,
2021

 

 

(Unaudited)

 

(Note)

Assets

 

 

 

 

Cash and cash equivalents

 

$

13,378

 

 

$

37,407

Accounts receivable from Healios, billed and unbilled

 

 

3,594

 

 

 

4,414

Prepaid expenses, deposits and other

 

 

5,916

 

 

 

5,711

Operating right-of-use assets, net

 

 

8,448

 

 

 

8,960

Property and equipment, net

 

 

3,868

 

 

 

3,692

Total assets

 

$

35,204

 

 

$

60,184

Liabilities and stockholders' equity

 

 

 

 

Accounts payable, accrued expenses and other current liabilities

 

$

31,123

 

 

$

24,391

Deferred revenue - Healios

 

 

?

 

 

 

3,340

Operating lease liabilities

 

 

9,263

 

 

 

9,766

Accounts payable to Healios

 

 

1,119

 

 

 

1,119

Advance from Healios

 

 

5,199

 

 

 

5,199

Other long-term liabilities

 

 

238

 

 

 

?

Total stockholders' equity

 

 

(11,738

)

 

 

16,369

Total liabilities and stockholders' equity

 

$

35,204

 

 

$

60,184

Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.

Athersys, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In Thousands, Except Per Share Amounts)

 

 

 

Three Months Ended
June 30,

 

 

2022

 

2021

Revenues

 

 

 

 

Contract revenue from Healios

 

$

2,316

 

 

$

?

 

Total revenues

 

 

2,316

 

 

 

?

 

Costs and expenses

 

 

 

 

Research and development

 

 

20,794

 

 

 

17,691

 

General and administrative

 

 

5,162

 

 

 

4,158

 

Depreciation

 

 

618

 

 

 

723

 

Total costs and expenses

 

 

26,574

 

 

 

22,572

 

Loss from operations

 

 

(24,258

)

 

 

(22,572

)

Other income, net

 

 

610

 

 

 

(27

)

Net loss and comprehensive loss

 

$

(23,648

)

 

$

(22,599

)

Net loss per share, basic and diluted

 

$

(0.09

)

 

$

(0.10

)

Weighted average shares outstanding, basic and diluted

 

 

259,570

 

 

 

222,436

 

 


These press releases may also interest you

at 14:45
The "European Defence Training and Simulation Growth Opportunities" report has been added to  ResearchAndMarkets.com's offering. This report explores the changing trends in the European defence T&S market in light of the changing geopolitical...

at 14:36
Dr. Lisa Damour, Ph.D. will guide parents through the emotional roller coaster of the middle and high school years during a live virtual webinar Wednesday hosted by Fusion Education Group....

at 14:33
The Premise Poll, in its latest regular political tracking poll, found that by a margin of 10 points, 42% - 32%, a plurality of Americans oppose sending undocumented individuals from the U.S.-Mexico border to cities in the North.  Nearly half of...

at 14:30
Conterra Ultra Broadband Holdings, Inc. ("Conterra Networks") today announced its continued investment in fiber network growth across Bossier Parish with its initial investment of $2.6 million and an additional estimated $3.5 million expected over 5...

at 14:28
namelesstm, the company backed by Gary Vee, Mechanism Capital and Guy Oseary's Sound Ventures, among others, has just released an innovative SaaS product to improve NFT project testing and quality assurance. The new NFT software, called StealthTest,...

at 14:24
On November 1, 2022, Equature will be releasing Equature Connect; a full-scale situational awareness tool to assist all facets of public safety. Equature Connect streams live video, real-time location, and audio directly from a 9-1-1 caller's...



News published on 11 august 2022 at 16:25 and distributed by: